Immunocellular Therapeutics Overview

  • Founded
  • 1987

Founded
  • Status
  • Public

  • Employees
  • 4

Employees
  • Stock Symbol
  • IMUC

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $0.65

  • (As of Thursday Closing)

Immunocellular Therapeutics General Information

Description

ImmunoCellular Therapeutics Ltd is seeking to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Contact Information

Website
www.imuc.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
  • 18375 Ventura Boulveard
  • Suite 381
  • Tarzana, CA 91356
  • United States
+1 (818) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunocellular Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.65 $0.66 $0.14 - $0.75 7.15K

Immunocellular Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2018 FY 2017 31-Dec-2017 FY 2016 31-Dec-2016 FY 2015 31-Dec-2015
EV 5,871 5,116 (5,895) 7,652
Revenue 0 0 0 0
EBITDA (5,650) (13,386) (20,723) (12,641)
Net Income (5,664) (14,312) (22,086) (12,791)
Total Assets 3,829 7,009 16,890 30,082
Total Debt 0 0 574 1,959
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immunocellular Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immunocellular Therapeutics‘s full profile, request access.

Request a free trial

Immunocellular Therapeutics Patents

Immunocellular Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2898474-A1 Cancer vaccines and vaccination methods Abandoned 14-Feb-2013 00000000000
EP-2956544-A1 Cancer vaccines and vaccination methods Granted 14-Feb-2013 00000000000
CA-2898457-A1 Ovarian cancer vaccines and vaccination methods Abandoned 14-Feb-2013 00000000000
EP-2956164-A1 Ovarian cancer vaccines and vaccination methods Withdrawn 14-Feb-2013 00000000000
EP-2956164-A4 Ovarian cancer vaccines and vaccination methods Withdrawn 14-Feb-2013 A61K39/0011 0
To view Immunocellular Therapeutics’s complete patent history, request access »

Immunocellular Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Gary Titus Chairman & Board Member
You’re viewing 1 of 6 executive team members. Get the full list »

Immunocellular Therapeutics Board Members (16)

Name Representing Role Since
0000 00000 Immunocellular Therapeutics Chairman & Board Member 000 0000
0000 00 00 Immunocellular Therapeutics Board Member 000 0000
You’re viewing 2 of 16 board members. Get the full list »

Immunocellular Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunocellular Therapeutics Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 02-Dec-2021 0000000 00 Biotechnology 0000 0000
Molecular Discoveries (Monoclonal Antibody Related Technology) 14-Feb-2008 Corporate Asset Purchase Buildings and Property
To view Immunocellular Therapeutics’s complete investments and acquisitions history, request access »